crta
Hrvatska znanstvena Sekcija img
bibliografija
3 gif
 Naslovna
 O projektu
 FAQ
 Kontakt
4 gif
Pregledavanje radova
Jednostavno pretraživanje
Napredno pretraživanje
Skupni podaci
Upis novih radova
Upute
Ispravci prijavljenih radova
Ostale bibliografije
Slični projekti
 Bibliografske baze podataka

Pregled bibliografske jedinice broj: 1003210

Časopis

Autori: Korpela, Taija; Cardenas-Jaen, Karina; Archibugi, Livia; Poropat, Goran; Capurso, Gabriele; de-Madaria, Enrique
Naslov: Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study
( Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study )
Izvornik: Digestive and liver disease (1590-8658) 50 (2018), 12; 1362-1365
Vrsta rada: članak
Ključne riječi: ERCP ; Endoscopic retrograde cholangiopancreatography ; Hydroxymethylglutaryl-CoA reductase inhibitors ; Prevention ; Prophylaxis
( ERCP ; Endoscopic retrograde cholangiopancreatography ; Hydroxymethylglutaryl-CoA reductase inhibitors ; Prevention ; Prophylaxis )
Sažetak:
BACKGROUND: Acute pancreatitis (AP) is the most common complication after endoscopic retrograde cholangiopancreatography (ERCP). Statins have been traditionally associated to an increased risk of AP, however, recent evidence suggests that statins may have a protective role against this disease. AIMS: Our primary aim is to investigate whether the use of statins has a protective effect against post-ERCP pancreatitis (PEP). Secondary outcomes are: to evaluate the effect of other drugs on the incidence of PEP ; to ascertain the relationship between the use of statins and the severity of PEP ; and to evaluate the effect of other risk and protective factors on the incidence of PEP. METHODS: STARK is an international multicenter prospective cohort study. Centers from Spain, Italy, Croatia, Finland and Sweden joined this study. The total sample size will include about 1016 patients, which was based on assuming a 5% incidence of PEP among non-statin (NSt) users, a 1-3 ratio of statin (St) and NSt consumers respectively, a 70% decrease in PEP among St consumers, an alpha-error of 0.05 and beta-error of 0.20. All patients aged ≥18 years scheduled for ERCP will be offered to enter the study. DISCUSSION: STARK study will ascertain whether statins, a safe, widely used and inexpensive drug, can modify the incidence of PEP.
Izvorni jezik: eng
Rad je indeksiran u
bazama podataka:
Current Contents Connect (CCC)
MEDLINE
Scopus
SCI-EXP, SSCI i/ili A&HCI
Science Citation Index Expanded (SCI-EXP) (sastavni dio Web of Science Core Collectiona)
Kategorija: Znanstveni
Znanstvena područja:
Kliničke medicinske znanosti
URL Internet adrese: https://www.dldjournalonline.com/article/S1590-8658(18)30879-X/fulltext
Broj citata:
Altmetric:
DOI: 10.1016/j.dld.2018.07.042
URL cjelovitog teksta:
Časopis izlazi u samo elektroničkom izdanju: NE
Google Scholar: Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study
Upisao u CROSBI: Goran Poropat (goran.poropat@uniri.hr), 26. Svi. 2019. u 20:14 sati



Verzija za printanje   za tiskati


upomoc
foot_4